Journal article

Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial

KR Lees, KW Muir, I Ford, JL Reid, AD Mendelow, PAG Sandercock, PMW Bath, KR Lees, I Ford, KW Muir, KR Lees, PMW Bath, C Chen, SM Davis, KW Muir, SJ Phillips, J Saver, G Vanhooren, C Forbes, G Murray Show all

LANCET | ELSEVIER SCIENCE INC | Published : 2004

Abstract

BACKGROUND: Magnesium is neuroprotective in animal models of stroke, and findings of small clinical pilot trials suggest potential benefit in people. We aimed to test whether intravenous magnesium sulphate, given within 12 h of stroke onset, reduces death or disability at 90 days. METHODS: 2589 patients were randomised within 12h of acute stroke to receive 16 mmol MgSO4 intravenously over 15 min and then 65 mmol over 24 h, or matching placebo. Primary outcome was a global endpoint statistic expressed as the common odds ratio for death or disability at day 90. Secondary outcomes were mortality and death or disability, variously defined as Barthel score less than 95, Barthel score less than 60..

View full abstract